【24h】

Urinary endothelin-1 as a marker of renal damage in sickle cell disease.

机译:尿内皮素-1作为镰状细胞病中肾损害的标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Sickle cell disease (SCD) affects the kidney by acute mechanisms as well as by insidious renal medullary/papillary necrosis, resulting in tubular defects, which increase the risk of dehydration and subsequent sickle crisis. Hypoxia has been reported to stimulate endothelin-1 (ET-1) synthesis by endothelial cells and also in the renal tubule. METHODS: This case-control study measured ET-1 in urine as a marker of its renal synthesis in asymptomatic SCD patients. Baseline plasma and urinary ET-1 levels were measured and followed during a water deprivation study and a subsequent administration of desmopressin. RESULTS: Urine and plasma levels of ET-1 were elevated in patients with SCD, compared with carefully matched African-French and African controls, and urine ET-1 excretion was associated with a marked urine-concentrating defect. Moreover, urinary ET-1 output was correlated with microalbuminuria in SCD patients. CONCLUSIONS: ET-1 is known to antagonize the tubular effects of vasopressin andto promote renal scarring; increased renal production of ET-1 could produce nephrogenic diabetes insipidus and dehydration in SCD patients through a combination of fibrosis and functional resistance to vasopressin. This study provides a rationale for trials with endothelin receptor antagonists in sickle cell disease nephropathy.
机译:背景:镰状细胞病(SCD)通过急性机制以及阴险的肾髓质/乳头状坏死影响肾脏,导致肾小管缺损,从而增加了脱水和随后发生镰刀病的风险。低氧据报道可刺激内皮细胞以及肾小管中内皮素1(ET-1)的合成。方法:这项病例对照研究测量了无症状SCD患者尿液中的ET-1,作为其肾脏合成的标志物。在禁水研究和随后的去氨加压素给药期间,测量并跟踪基线血浆和尿ET-1水平。结果:与精心配对的非洲-法国和非洲对照组相比,SCD患者的尿液和血浆中ET-1的水平升高,尿ET-1的排泄与明显的尿液浓缩缺陷有关。此外,在SCD患者中尿ET-1的输出与微量蛋白尿有关。结论:已知ET-1可拮抗血管加压素的肾小管作用并促进肾脏瘢痕形成。通过纤维化和抗血管加压素的功能性结合,ET-1肾脏产量的增加可导致SCD患者肾病性尿崩症和脱水。这项研究为镰状细胞病肾病中内皮素受体拮抗剂的试验提供了理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号